WEP CLINICAL ANNOUNCES NEW INVESTMENT MADE BY THE JORDAN COMPANY Morrisville, NC, USA & London, UK – November 29, 2021 – WEP Group Holdings Limited (WEP Clinical) is pleased to announce the closure of an investment [...]
WEP CLINICAL PARTNERS WITH KINIKSA TO LAUNCH ARCALYST NAMED PATIENT PROGRAM Morrisville, NC, USA & London, UK – August 17, 2021 – WEP Clinical LTD (WEP), a specialist services company that works with drug developers [...]
WEP CLINICAL EXECUTES MASTER SERVICES AGREEMENT WITH MEDLAB TO BRING NANABIS™ AND NANOCBD™ TO PATIENTS IN UK AND EUROPE VIA ETHICAL NAMED PATIENT PROGRAMMES Morrisville, NC, USA & London, UK – July 19, 2021 – [...]
WEP CLINICAL EXPANDS AVAILABILITY OF XENLETA® (LEFAMULIN) NAMED PATIENT PROGRAM IN PARTNERSHIP WITH NABRIVA THERAPEUTICS Morrisville, NC, USA & London, UK – March 25, 2021 – WEP Clinical (WEP) and Nabriva Therapeutics (Nabriva) are pleased [...]
WEP CLINICAL EXTENDS PARTNERSHIP WITH BTG SPECIALTY PHARMACEUTICALS BY GAINING WORLDWIDE (EX-US) DISTRIBUTION RIGHTS FOR DIGIFAB® Morrisville, NC, USA & London, UK – March 1, 2021 – WEP Clinical (WEP) announced today that it has extended [...]
